Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial

BACKGROUND: The sodium/glucose cotransporter 2 inhibitor empagliflozin has cardiorenal protective properties through mechanisms beyond glucose control. In this study we assessed whether empagliflozin modifies renal oxygenation as a possible mechanism of renal protection, and determined the metabolic...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Am Heart Assoc
Autori principali: Zanchi, Anne, Burnier, Michel, Muller, Marie‐Eve, Ghajarzadeh‐Wurzner, Arlène, Maillard, Marc, Loncle, Nicolas, Milani, Bastien, Dufour, Nathalie, Bonny, Olivier, Pruijm, Menno
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7670540/
https://ncbi.nlm.nih.gov/pubmed/32567439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.016173
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi